Interleukin 32 as a biomarker of type 1 diabetes
AssigneeTurun Yliopisto
InventorsJuhi SOMANI, Soile TUOMELA, Henna KALLIONPÄÄ, Riitta LAHESMAA, Harri LÄHDESMÄKI, Riikka LUND, Mikael KNIP
Life of this patent
Estimating the term…
Abstract
The present invention relates to interleukin 32 (IL-32) as a predictive marker of Type 1 diabetes (T1D). The invention also relates to a method of predicting an individual's risk of or progression towards T1D, and to a kit for use in said method.
Claims14
A method of determining Type 1 Diabetes (T1D) in an individual, wherein the method comprises assessing the expression level of interleukin 32 (IL-32) in a sample obtained from said individual.
(canceled)
A kit comprising one or more testing agents capable of detecting the expression level of IL-32 in a biological sample obtained from an individual whose T1D is to be determined.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.